OncoMatch/Clinical Trials/NCT06921785
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Is NCT06921785 recruiting? Yes, currently enrolling (Sep 2026). This Phase 3 trial studies multiple treatments including Tremelimumab and Rilvegostomig for hepatocellular carcinoma.
Treatment: Tremelimumab · Rilvegostomig · Bevacizumab · Atezolizumab — This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in participants with advanced HCC who are not amenable to curative therapy or locoregional therapy
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage III, IV, BCLC STAGE B (NOT ELIGIBLE FOR LOCOREGIONAL THERAPY), BCLC STAGE C (other)
Locally advanced or metastatic and/or unresectable HCC; BCLC stage B (that is not eligible for locoregional therapy) or stage C; Disease that is not amenable to curative surgical and/or locoregional therapies
Performance status
ECOG 0–1(Restricted strenuous activity)
WHO/ECOG performance status of 0 or 1
Prior therapy
Cannot have received: anti-CTLA-4 therapy
Prior treatment with anti-CTLA-4
Cannot have received: anti-TIGIT therapy
Prior treatment with anti-TIGIT
Cannot have received: systemic therapy for intermediate, advanced, or metastatic HCC
Must not have received prior systemic therapy for intermediate, advanced, or metastatic HCC
Lab requirements
Blood counts
Adequate organ and bone marrow function measured during the screening period
Liver function
Child-Pugh Score class A
Child-Pugh Score class A; Adequate organ and bone marrow function measured during the screening period
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · New Haven, Connecticut
- Research Site · Newark, Delaware
- Research Site · Jacksonville, Florida
- Research Site · Atlanta, Georgia
- Research Site · Atlanta, Georgia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06921785 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage III or IV or BCLC STAGE B (NOT ELIGIBLE FOR LOCOREGIONAL THERAPY) or BCLC STAGE C is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages